News
The death will likely further stoke safety concerns around Sarepta's gene therapies, as well as raise questions around the ...
According to multiple reports, a 51-year-old man with limb-girdle muscular dystrophy died from acute liver failure after ...
Shares of Sarepta Therapeutics (NASDAQ: SRPT) plunged 26.85% in Friday pre-market after a clinical trial participant died ...
Shares of Sarepta Therapeutics plummeted nearly 30% premarket Friday following a report that a third patient has died during ...
These were the most active stocks ahead of Friday's market open: Sarepta Therapeutics Inc.'s stock tumbled 27% after the company said another patient died following gene-therapy treatment, Bloomberg ...
The pharma company said it would lay off a third of its workforce and add a black-box warning to its controversial gene ...
The drastic cost-cutting move follows the deaths of two teenagers that forced the company to restrict usage of its gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results